Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
42
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
InnoCare Pharma
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
Key Takeaways Heavy dependence on a single drug and regulatory risks threaten profitability and revenue stability, especially if late-stage trials or approvals face setbacks. Heightened cost pressures, geopolitical barriers, and aggressive R&D outlays could limit global expansion, compress margins, and suppress future earnings per share.
View narrative
HK$8.21
FV
138.8% overvalued
intrinsic discount
29.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Teladoc Health
AN
AnalystLowTarget
Consensus Narrative from 20 Analysts
Rising Global Regulations And Healthcare Pressures Will Lower Valuation
Key Takeaways Rising compliance and operational costs, alongside intensifying competition and reimbursement uncertainty, threaten Teladoc's margins and long-term profitability across core and emerging business segments. Limited digital infrastructure and healthcare access in key markets restrict addressable growth, despite greater virtual care adoption and expanded service offerings.
View narrative
US$7.00
FV
7.4% overvalued
intrinsic discount
-0.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Veris Residential
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Jersey City Exposure Will Raise Risks Yet Renovations Will Help
Key Takeaways Heavy reliance on luxury multifamily housing and geographic concentration increases exposure to demand shifts, local regulation, and potential earnings volatility. Rising operating costs and regulatory pressures threaten to offset recent efficiency gains and constrain rental income growth and margin expansion.
View narrative
US$15.00
FV
5.1% undervalued
intrinsic discount
1.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Everest Medicines
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Rising Regulatory And Pricing Pressures Will Erode Margins Despite Progress
Key Takeaways Regulatory headwinds, geopolitical tensions, and price controls threaten market access, profitability, and expansion for Everest Medicines. Heavy reliance on in-licensing and rising competition jeopardize margins, revenue growth, and prospects for sustained earnings.
View narrative
HK$25.61
FV
175.7% overvalued
intrinsic discount
75.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
NeoGenomics
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Underutilized Pharma Services And Execution Risks Will Threaten Demand Yet Efficiency Will Emerge
Key Takeaways Ongoing challenges in pharma services, competitive threats, and regulatory risks are pressuring growth, leading to missed targets and concerns about sustaining long-term momentum. Heavy investment in operational upgrades and portfolio expansion brings potential efficiencies but increases upfront costs, execution risks, and delays in profitability improvement.
View narrative
US$6.50
FV
4.5% undervalued
intrinsic discount
8.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Robosense Technology
AN
AnalystLowTarget
Consensus Narrative from 15 Analysts
Falling Prices And Intensifying Competition Will Undercut LiDAR Margins
Key Takeaways Intensifying price competition and a shift toward lower-margin solutions are pressuring profitability and stalling margin recovery. Rising geopolitical risks and disruptive sensor technologies threaten international expansion and long-term revenue growth.
View narrative
HK$23.54
FV
51.9% overvalued
intrinsic discount
42.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Jamf Holding
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Regulatory Hurdles And Competition Will Restrict Margins Yet Allow Progress
Key Takeaways Heavy reliance on Apple and standalone services exposes Jamf to risks from evolving enterprise needs, alternative platforms, and industry consolidation. Growing regulatory, compliance, and R&D challenges could limit margin expansion and slow revenue growth despite operational gains and market demand.
View narrative
US$10.00
FV
16.1% undervalued
intrinsic discount
9.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Confluent
AN
AnalystLowTarget
Consensus Narrative from 31 Analysts
Competition And Regulation Will Limit Cloud Growth But Enable Recovery
Key Takeaways Persistent customer cost-cutting and slower adoption of new use cases may limit revenue growth despite strong demand and new offerings. Rising competition, regulatory costs, and high marketing spend create uncertainty around sustainable margin improvements and long-term scalability.
View narrative
US$20.00
FV
11.1% undervalued
intrinsic discount
14.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Glaukos
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Intensified Competition And Reimbursement Cuts Will Impair Prospects
Key Takeaways Reimbursement cuts, shifting treatment preferences, and intensifying competition threaten Glaukos' pricing power, market share, and long-term revenue growth. Heavy reliance on few products and high R&D spending expose Glaukos to earnings volatility and margin pressure if commercialization or adoption hurdles persist.
View narrative
US$74.28
FV
21.0% overvalued
intrinsic discount
21.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 10 hours ago
author updated this narrative
Value any company in seconds
Popular companies